Suchergebnisse - "Epperla, Narendranath"

PubPharm (227)

1

Response to : Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi et al

enthalten in: Journal for immunotherapy of cancer | 2024

von Sayed, A. | Munir, M. | Poliner, M. | +3

2

Patterns of Disease Progression in patients with newly diagnosed Primary Central Nervous System Lymphoma Following Treatment with High-Dose Methotrexate

enthalten in: ResearchSquare.com | 2024

von Cappelli, L. | Kayne, A. | Newman, J. | +6

3

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-cell nHL Treated with CAR-T

enthalten in: Blood advances | 2024

von Karmali, R. | Machhi, R. | Epperla, N. | +28

4

Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma

enthalten in: Blood advances | 2024

von Denlinger, N. | Song, N. | Zhang, X. | +31

5

Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy

enthalten in: Blood advances | 2024

von Melody, M. | Epperla, N. | Shouse, G. | +23

6

Cardiovascular toxicities associated with bispecific T-cell engager therapy

enthalten in: Journal for immunotherapy of cancer | 2024

von Sayed, A. | Munir, M. | Ghazi, S. | +15

7

Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy

enthalten in: Bone marrow transplantation | 2024

von Iqbal, M. | Jagadeesh, D. | Chavez, J. | +19

8

Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States : a real-world analysis

enthalten in: Blood advances | 2024

von Epperla, N. | Zhao, Q. | Moyo, T. | +12

9

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

enthalten in: Blood | 2024

von Neelapu, S. | Chavez, J. | Sehgal, A. | +23

CommentIn: Blood. 2024 Feb 8;143(6):475-476. - PMID 38329775

10

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma

enthalten in: Blood advances | 2023

von Steiner, R. | Hwang, S. | Khurana, A. | +28

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[23]